close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Tris Pharma, Inc.

News headline image
Tris Pharma Announces FDA Acceptance of NDA for Once-Nightly, Low-Sodium Oxybate Product for Narcolepsy and Idiopathic Hypersomnia
From Tris Pharma, Inc.
Via Business Wire
News headline image
Tris Pharma Announces Acceptance of New Review Article Highlighting Challenges of Treating Moderate-to-Severe Acute Pain with Currently Available Drugs
From Tris Pharma, Inc.
Via Business Wire
News headline image
Tris Pharma Showcases a Novel Mechanism of Dual-NOP/MOP (NMR) Agonism for the Treatment of Moderate-to-Severe Acute Pain and Encores Positive Phase 3 Data at 2025 Annual PAINWeek Meeting in Las Vegas
From Tris Pharma, Inc.
Via Business Wire
News headline image
Tris Pharma to Debut Positive Results of Intranasal (Snorting) Human Abuse Potential Study of Cebranopadol, an Investigational First-In-Class Oral Dual-NMR Agonist for the Treatment of Moderate-to-Severe Pain, at the 2025 CPDD Annual Meeting
From Tris Pharma, Inc.
Via Business Wire
News headline image
Tris Pharma to Unveil Positive Phase 3 Results including a Strong Safety Profile Showcasing the Potential of Cebranopadol, an Investigational First-in-Class Dual-NMR Agonist for the Treatment of Pain, at the 2025 ASRA Annual Meeting
From Tris Pharma, Inc.
Via Business Wire
News headline image
Tris Pharma to Present New Data at AAPM PainConnect Annual Meeting and Showcase Potential of Cebranopadol, a First-in-Class Investigational Dual-NMR Agonist for the Treatment of Pain
From Tris Pharma, Inc.
Via Business Wire
News headline image
Tris Pharma Announces Positive Results from ALLEVIATE-2 Phase 3 Pivotal Trial for Cebranopadol, an Investigational First-in-Class Oral Dual-NMR Agonist, for the Treatment of Moderate-to-Severe Acute Pain
From Tris Pharma, Inc.
Via Business Wire
News headline image
Tris Pharma Reports Positive Clinical Results of Intranasal Human Abuse Potential Study Indicating Low Abusability of Cebranopadol, an Investigational, First-in-Class Oral Dual-NMR Agonist for the Treatment of Moderate-to-Severe Pain
From Tris Pharma, Inc.
Via Business Wire
News headline image
Tris Pharma Announces Positive Results from ALLEVIATE-1 Phase 3 Clinical Trial of Cebranopadol, an Investigational First-in-Class Oral Dual-NMR Agonist, for the Treatment of Moderate-to-Severe Acute Pain
From Tris Pharma, Inc.
Via Business Wire
News headline image
Tris Pharma Secures Additional ex-US Approvals to Expand Global Availability of Quillivant XR and QuilliChew ER for the Treatment of Attention Deficit Hyperactivity Disorder
From Tris Pharma, Inc.
Via Business Wire
News headline image
Tris Pharma’s Once-Daily ADHD Medication, ONYDA XR (clonidine hydrochloride) Extended-Release Oral Suspension, Now Available in the United States
From Tris Pharma, Inc.
Via Business Wire
News headline image
Tris Pharma Promotes Manesh Naidu to Chief Commercial Officer
From Tris Pharma, Inc.
Via Business Wire
News headline image
Findings Presented at PAINWeek 2024 Demonstrate Tris Pharma’s Investigational, First-in-Class Therapy Cebranopadol Provides Potent, Prolonged Pain Relief with Improved Safety Over Oxycodone
From Tris Pharma, Inc.
Via Business Wire
News headline image
Tris Pharma Initiates ALLEVIATE-1 and ALLEVIATE-2, Pivotal Phase 3 Trials Investigating Cebranopadol, a First-in-Class Compound with a Novel Mechanism of Action to Treat Pain
From Tris Pharma, Inc.
Via Business Wire
News headline image
Tris Pharma Presents New Clinical Data Demonstrating Robust Safety and Efficacy of Investigational, First-in-Class Therapy Cebranopadol for Treatment of Pain
From Tris Pharma, Inc.
Via Business Wire
News headline image
Cranbury Pharmaceuticals Receives U.S. FDA Approval for First Generic Version of Emflaza® Oral Suspension (deflazacort) for Duchenne Muscular Dystrophy
From Tris Pharma, Inc.
Via Business Wire
News headline image
Tris Pharma Receives U.S. FDA Approval for Once-Daily ONYDA XR (clonidine hydrochloride) Extended-Release Oral Suspension, the First-and-Only Liquid Non-Stimulant ADHD Medication
From Tris Pharma, Inc.
Via Business Wire
News headline image
Tris Pharma Launches Digital Health Business to Develop and Commercialize Digital Products for ADHD
From Tris Pharma, Inc.
Via Business Wire
News headline image
Tris Pharma Appoints Michael Magee as Vice President, Quality & Compliance
From Tris Pharma, Inc.
Via Business Wire
News headline image
Tris Pharma Partners with Perigon Pharmacy 360 to Enhance Access to DYANAVEL® XR Tablets for the Treatment of Attention Deficit Hyperactivity Disorder
From Tris Pharma, Inc.
Via Business Wire
News headline image
Tris Pharma Secures First ex-US Authorizations for Quillivant ER Oral Suspension and Quillivant ER Chewable Tablet for the Treatment of Attention Deficit Hyperactivity Disorder
From Tris Pharma, Inc.
Via Business Wire
News headline image
Tris Pharma Presents Data Reinforcing Limited Abuse Potential of Investigational Pain Therapy Cebranopadol at the 2023 PAINWeek Conference
From Tris Pharma, Inc.
Via Business Wire
News headline image
Tris Pharma Awarded Five-Year Grant of Up to $16.6M From the NIH's National Institute on Drug Abuse to Advance Cebranopadol for the Treatment of Opioid Use Disorder
From Tris Pharma, Inc.
Via Business Wire
News headline image
Tris Pharma Expands Leadership Team as Company Broadens Commercial Portfolio and Progresses Clinical Pipeline
From Tris Pharma, Inc.
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today